all report title image
  • Published On : Apr 2022
  • Code : CMI5001
  • Industry : Pharmaceutical
  • Pages : 208
  • Formats :

Benzodiazepines are a class of drugs that can be used to treat a variety of ailments such as anxiety, insomnia, seizures, social phobia, and panic disorder. Benzodiazepine are used for premedication before medical procedures. These drugs are normally safe and effective when they are used for a short period of time, but in terms of long-term usage, it can lead to tolerance, dependency, and other side effects. According to the U.S. Food and Drug Administration (U.S. FDA), in 2019, it was estimated that approximately 92 million benzodiazepine prescriptions were dispensed from the U.S. outpatient retail and mail-order pharmacies.

Benzodiazepines are commonly administered via the oral and intravenous routes. They may also be administered through rectal route, intranasal route, and intramuscular route. The benzodiazepine treatment provides better quality of life for all those affected by mental illness, their carers, family and friends.

Global Benzodiazepine Drugs Market - Impact of the Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic is expected to limit growth of the global benzodiazepine drugs market over the forecast period. High prevalence of stress and anxiety surge the demand for benzodiazepine drugs for their treatment, which is expected to drive the growth of the segment during the forecast period. For instance, according to the publication by BioMed Central (BMC), July 2020, the prevalence of stress, anxiety, and depression among the general population during the COVID-19 pandemic was analyzed globally. The prevalence of stress in 5 studies with a total sample size of 9074 was around 29.6%, the prevalence of anxiety in 17 studies with a sample size of 63,439 was around 31.9%, and the prevalence of depression in 14 studies with a sample size of 44,531 people was 33.7%.

Moreover, there was a decrease in the prescription of benzodiazepines before COVID-19 pandemic, but during the COVID-19 pandemic, there was an increase in the prescription rates. This is expected to increase the growth of the global benzodiazepine drugs market, over the forecast period. For instance, in October 2021, according to an article published in the National Center for Biotechnology Information (NCBI), globally, benzodiazepine prescribing decreased from January 2018 to March 2020. However, there was a slight increase in April 2020 among women. For women, the prescribing rates decreased from 5.61% in January 2018 to 5.00% in January 2020, but increased to 5.32% in April 2020 due to the COIVD-19 pandemic.

The global benzodiazepine drugs market is estimated to be valued at US$ 3,050.4 Mn in 2022 and is expected to exhibit a CAGR of 3.2% over the forecast period (2022-2030)  

Figure 1: Global Benzodiazepine Drugs Market Share, (%), Analysis, By Product, 2022

 Benzodiazepine Drugs  | Coherent Market Insights

Market players are indulged in developing innovative medicines for the treatment of seizures in children, this is expected to drive growth of the global benzodiazepine drugs market over the forecast period

Market players are engaged in the development of innovative medicines for the treatment of seizures. This is expected to drive growth of the global benzodiazepine drugs market over the forecast period. For instance, in September 2021, Neurelis, Inc., an innovation-driven neuroscience company initiated clinical program to investigate the use of VALTOCO (diazepam nasal spray) in children with epilepsy, aged two to five as a treatment for seizure clusters. Currently, the study is in the Phase I/II of the clinical trial. The study is expected to be finished by December 2022.

Increasing product approvals by the regulatory authorities is expected to drive the growth of the market over the forecast period

Product approvals by the regulatory authorities is expected to drive growth of the global benzodiazepine drugs market over the forecast period. For instance, in August 2021, Loreev XR (extended-release lorazepam) distributed by Almatica Pharma LLC (a privately held, U.S. pharmaceutical company), was approved by the U.S. Food and Drug Administration (FDA). It is a once daily benzodiazepine formulation which is indicated for the treatment of anxiety disorders, preoperative sedation, anterograde amnesia, and status epilepticus in adults.

CMI table icon

Benzodiazepine Drugs Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 3,050.4 Mn
Historical Data for: 2018 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 3.2% 2030 Value Projection:

US$ 3,917.0 Mn

Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product: Long Acting Benzodiazepine (Chlordiazepoxide, Diazepam, Lorazepam, Alprazolam, Clonazepam, Others), Short Acting Benzodiazepine (Temazepam, Midazolam, Triazolam, Others)
  • By Application: Anxiety Disorders, Nervousness, Sedation, Seizures, Alcohol Withdrawal, Others
  • By Route of Administration: Oral, Injectables, Others
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

F.Hoffmann-La Roche Ltd., Torrent Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Pfizer Inc., Viatris Inc. (Mylan N.V.), Labiana Pharmaceuticals, Bausch Health Companies, Inc., Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Par Pharmaceutical, and Intas Pharmaceuticals Ltd.

Growth Drivers:
  • Increasing research and development activities
  • Increasing product approvals by the regulatory authorities
Restraints & Challenges:
  • Product recalls
  • Benzodiazepines are banned in some countries

Global Benzodiazepine Drugs Market – Restraints

The increasing benzodiazepine drugs recalls is expected to hamper growth of the global benzodiazepine drugs market over the forecast period. For instance, on  March 7, 2022, Wockhardt UK Ltd, a generic pharmaceutical company, announced that the company is recalling a batch of Diazepam RecTubes 2.5mg rectal solution, due to an out of specification result for assay during routine stability testing.

Similarly, in May 2017, F. Hoffmann-La Roche AG, a multinational healthcare company, issued an urgent medicine recall to retrieve all the batches of Valium 5mg in Australia, after the company found evidence of product tampering within its supply chain.

Moreover, benzodiazepine is banned in some of the countries, such as the U.A.E, etc., due to various reasons such as addiction to the benzodiazepine drugs, etc. Thus, the above factors are expected to restrain the growth of the global benzodiazepine drugs market over the forecast period.

Global Benzodiazepine Drugs Market – Regional Analysis

On the basis of region, global benzodiazepine drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa

Among regions, North America benzodiazepine drugs market is expected to hold a dominant position during the forecast period, owing to the submitting applications for new drugs and is expected to drive growth of the North America benzodiazepine drugs market over the forecast period. For instance, in 2021, Aquestive Therapeutics, Inc., a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) accepted for filling the resubmission of the New Drug Application (NDA) for Libervant (diazepam) buccal film for the management of seizure clusters.

Furthermore, Europe is also estimated to witness significant growth in the global benzodiazepine drugs market, owing to increasing product approvals by the regulatory authorities. For instance, in 2021, Acacia Pharma Group plc, a manufacturer and distributor of pharmaceutical products, headquartered in the U.K., launched BYFAVO (remimazolam), a short acting benzodiazepine. BYFAVO was approved by the U.S. Food and Drug Administration (FDA) on July 2, 2020. It is indicated for the induction and maintenance of procedural sedation in adults, who are undergoing procedures lasting 30 minutes or less.

Figure 2: Global Benzodiazepine Drugs Market (US$ Mn), by Region, 2022

Benzodiazepine Drugs  | Coherent Market Insights

Global Benzodiazepine Drugs Market – Competitive Landscape

Major players operating in the global benzodiazepine drugs market include F.Hoffmann-La Roche Ltd., Torrent Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Pfizer Inc., Viatris Inc. (Mylan N.V.), Labiana Pharmaceuticals, Bausch Health Companies, Inc., Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Par Pharmaceutical, and Intas Pharmaceuticals Ltd.

Benzodiazepines are a group of prescription-only medicines that have a sedating/hypnotic and calming effects on the nervous system. Some of the examples of benzodiazepines that are used for the treatment of anxiety, seizures, etc. are diazepam, lorazepam, oxazepam, temazepam, and alprazolam. Most of the benzodiazepine drugs are available as generics as most of the patent are expired. The benzodiazepine are still widely recognizable under brand names such as Valium or Xanax. They come in the form of tablet and capsule forms and some are available for intravenous forms to be used in hospital settings.

Market Dynamics

Market players are engaged in facility expansion, in order to expand its manufacturing facility and product portfolio. This is expected to drive growth of the global benzodiazepine drugs market over the forecast period. For instance, in January 2018, Torrent Pharmaceuticals Ltd. acquired Bio-Pharm, Inc., a U.S.-based generic pharmaceuticals and over-the-counter (OTC) Company which also included a U.S. Food and Drug Administration (FDA) registered 75,000 sqft manufacturing facility in the U.S.

Key players are engaged in receiving approval for their products from the regulatory authorities. This is expected to drive growth of the market over the forecast period. For instance, in October 2018, Amneal Pharmaceuticals, Inc., an American biopharmaceutical company announced that a generic version of Onfi (clobazam) tablets, 10 mg and 20 mg for oral use, CIV, and Onfi (clobazam) oral suspension, 2.5 mg/mL, CIV, has been approved by the U.S. Food and Drugs Administration.

Key features of the study:

  • This report provides an in-depth analysis of the global benzodiazepine drugs market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global benzodiazepine drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include F.Hoffmann-La Roche Ltd., Torrent Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Pfizer Inc., Viatris Inc. (Mylan N.V.), Labiana Pharmaceuticals, Bausch Health Companies, Inc., Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Par Pharmaceutical, and Intas Pharmaceuticals Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global benzodiazepine drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global benzodiazepine drugs market

Detailed Segmentation:

  • Global Benzodiazepine Drugs Market, By Product:
    • Long Acting Benzodiazepine
      • Chlordiazepoxide
      • Diazepam
      • Lorazepam
      • Alprazolam
      • Clonazepam
      • Others
    • Short Acting Benzodiazepine
      • Temazepam
      • Midazolam
      • Triazolam
      • Others
  • Global Benzodiazepine Drugs Market, By Application:
    • Anxiety Disorders
    • Nervousness
    • Sedation
    • Seizures
    • Alcohol Withdrawal
    • Others
  • Global Benzodiazepine Drugs Market, By Route of Administration:
    • Oral
    • Injectables
    • Others
  • Global Benzodiazepine Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Benzodiazepine Drugs Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Hoffmann-La Roche Ltd.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Torrent Pharmaceuticals Ltd.
    • Mallinckrodt Pharmaceuticals
    • Pfizer Inc.
    • Viatris Inc. (Mylan N.V.)
    • Labiana Pharmaceuticals
    • Bausch Health Companies, Inc.
    • Teva Pharmaceutical Industries Ltd.,
    • Amneal Pharmaceuticals LLC
    • Sun Pharmaceutical Industries Ltd.
    • Aurobindo Pharma
    • Par Pharmaceutical
    • Intas Pharmaceuticals Ltd

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global benzodiazepine drugs market is expected to exhibit a CAGR of 3.2% during the forecast period (2022-2030).
The market is estimated to be valued at US$ 3,050.4 Mn in 2022.
F.Hoffmann-La Roche Ltd., Torrent Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Pfizer Inc., Viatris Inc. (Mylan N.V.), Labiana Pharmaceuticals, Bausch Health Companies, Inc., Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Par Pharmaceutical, and Intas Pharmaceuticals Ltd. are some of the prominent players operating in the market.
The market is expected to be valued at US$ 3,917.0 Mn in 2030.
North America is the prominent region in the market.
Long acting benzodiazepine drugs is the prominent segment among the product type segment in the market.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo